Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgo biloba extract (GB or EGb) is an investigational herbal extract being evaluated by Assiut University for the treatment of asymmetrical intrauterine growth restriction (IUGR) in pregnancy. The extract is composed of terpene trilactones, including ginkgolides A, B, C, J and bilobalide, as well as flavonol glycosides such as kaempferol, quercetin, and isorhamnetin. Its therapeutic mechanism in IUGR involves anti-inflammatory and antioxidant actions that are believed to improve placental function and feto-maternal blood flow. Clinical research conducted at Assiut Women's Health Hospital has demonstrated that oral administration of the extract during the third trimester can significantly improve estimated fetal weight and Doppler blood flow parameters in pregnant women with IUGR.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgo biloba extract.